Bleeding and thrombosis outcomes in hospitalised COVID-19 patients on low-molecular-weight heparin and antiplatelet therapy
DOI:
https://doi.org/10.7196/SAMJ.2022.v112i7.16434Keywords:
COVID-19, thrombosisAbstract
Background. An increased incidence of thromboembolic events in hospitalised COVID‐19 patients has been demonstrated despite the use of low‐molecular‐weight heparin (LMWH). Antiplatelet therapy prior to admission and early in the disease course has been hypothesised to be protective against thrombosis.
Objectives. To describe the bleeding and thrombosis outcomes in hospitalised patients with confirmed COVID‐19 receiving LMWH, with and without concomitant antiplatelet therapy. Secondary objectives were to explore predictors of bleeding and thrombosis outcomes, and dosing practices of antiplatelet therapy and LMWH.
Methods. We conducted a descriptive, cross‐sectional study of bleeding and thrombosis outcomes at Tygerberg Academic Hospital, Cape Town, South Africa, during the first COVID‐19 wave, in 808 hospitalised patients with confirmed COVID‐19 receiving LMWH with and without concomitant antiplatelet therapy. Multivariate logistic regression analysis was performed if predictors were deemed statistically and clinically significant.
Results. Patients receiving both LMWH and antiplatelet therapy had similar bleeding outcomes compared with patients only receiving LMWH (odds ratio (OR) 1.5; 95% confidence interval (CI) 0.6 ‐ 4.0). Patients receiving both LMWH and antiplatelet therapy had increased odds of developing thrombosis compared with patients only receiving LMWH (OR 4.8; 95% CI 2.1 ‐ 10.7).
Conclusion. The bleeding risk in COVID‐19 patients receiving both LMWH and antiplatelet therapy was not significantly increased. A potentially higher risk of thrombosis in patients receiving LMWH and antiplatelet therapy was observed. However, this could reflect confounding by indication. Randomised studies are required to further evaluate the use of antiplatelet therapy to treat hospitalised patients with COVID‐19.
References
World Health Organization. WHO Director‐General’s opening remarks at the media briefing on COVID‐19 – 11 March 2020. https://www.who.int/director‐general/speeches/detail/who‐ director‐general‐s‐opening‐remarks‐at‐the‐media‐briefing‐on‐ covid‐19‐‐‐11‐march‐2020 (accessed 25 May 2021).
Worldometer. Coronavirus: South Africa. 2,383,490 cases and 70,018 deaths. https://www.worldometers.info/coronavirus/ country/south‐africa/ (accessed 4 December 2021).
Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID‐19: A prospective cohort study. Ann Intern Med 2020;173(4):268‐277. https://doi.org/10.7326/M20‐2003
Becker RC. COVID‐19 update: COVID‐19‐associated coagulopathy. J Thromb Thrombolysis 2020;50(1):54‐67. https:// doi.org/10.1007/s11239‐020‐02134‐3
Brunton LL, Hilal‐Dandan R, Knollmann BC. In: Shanahan JF, Lebowitz H, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw‐Hill Education, 2018:588.
Menter T, Haslbauer JD, Nienhold R, et al. Post‐mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology 2020;77(2):198‐209. https://doi.org/10.1111/ his.14134
Bikdeli B, Madhavan MV, Jimenez D, et al. COVID‐19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow‐up. J Am Coll Cardiol 2020;75(23):2950‐2973. https://doi.org/10.1016/j. jacc.2020.04.031
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS‐CoV‐2 infection: A multicenter prospective cohort study. Intensive Care Med 2020;46(6):1089‐1098. https:// doi.org/10.1007/s00134‐020‐06062‐x
Llitjos J, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. J Thromb Haemost 2020;18(7):1743‐1746. https://doi. org/10.1111/jth.14869
Oxley TJ, Mocco J, Majidi S, et al. Large‐vessel stroke as a presenting feature of COVID‐19 in the young. N Engl J Med 2020;382(20):e60. https://doi.org/10.1056/NEJMc2009787
Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalised patients with COVID‐19 in a New York City health system. JAMA 2020;324(8):799‐801. https://doi. org/10.1001/jama.2020.13372
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID‐19. Thromb Res 2020;191:145‐147. https://doi.org/10.1016/j. thromres.2020.04.013
Marietta M, Vandelli P, Mighali P, Vicini R, Coluccio V, D’Amico R. Randomised controlled trial comparing efficacy and safety of high versus low low‐molecular weight heparin dosages in hospitalised patients with severe COVID‐19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID‐19 HD): A structured summary of a study protocol. Trials 2020;21(1):574. https:// doi.org/10.1186/s13063‐020‐04475‐z
ClinicalTrials.gov. https://clinicaltrials.gov/ (accessed December 2021).
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID‐19. J Thromb
Haemost 2020;18(7):1559‐1561. https://doi.org/10.1111/jth.14849
Battinelli EM. COVID‐19 concerns aggregate around platelets. Blood 2020;136(11):1221‐1223. https://
doi.org/10.1182/blood.2020007805
Zhou X, Li Y, Yang Q. Antiplatelet therapy after percutaneous coronary intervention in patients with COVID‐19: Implications from clinical features to pathologic findings. Circulation 2020;141(22):1736‐ 1738. https://doi.org/10.1161/CIRCULATIONAHA.120.046988
Godino C, Scotti A, Maugeri N, et al. Antithrombotic therapy in patients with COVID‐19? – Rationale and evidence. Int J Cardiol 2021;324:261‐266. https://doi.org/10.1016/j.ijcard.2020.09.064
Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe COVID‐19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res 2020;158:104950. https://doi.org/10.1016/j.phrs.2020.104950
Lang ZW, Zhang LJ, Zhang SJ, et al. A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology 2003;35(6):526‐531. https://doi.org/10.1080/00313020310001619118
Peters RJG, Mehta SR, Fox KAA, et al. Effects of aspirin dose when used alone or in combination with
clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108(14):1682‐1687. https://doi. org/10.1161/01.CIR.0000091201.39590.CB
Van Rein N, Heide‐Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 2019;139(6):775‐786. https://doi.org/10.1161/CIRCULATIONAHA.118.036248
Pavoni V, Gianesello L, Pazzi M, Stera C, Meconi T, Frigieri FC. Venous thromboembolism and bleeding in critically ill COVID‐19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Thromb Res 2020;196:313‐317. https://doi.org/10.1016/j. thromres.2020.09.013
Banik J, Mezera V, Köhler C, Schmidtmann M. Antiplatelet therapy in patients with COVID‐19: A retrospective observational study. Thromb Update 2021;2:100026. https://doi.org/10.1016/j. tru.2020.100026
Sivaloganathan H, Ladikou EE, Chevassut T. COVID‐19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol 2020;190(4):e192‐e195. https://doi.org/10.1111/bjh.16968
Tremblay D, van Gerwen M, Alsen M, et al. Impact of anticoagulation prior to COVID‐19 infection: A propensity score‐matched cohort study. Blood 2020;136(1):144‐147. https://doi.org/10.1182/ blood.2020006941
Russo V, di Maio M, Attena E, et al. Clinical impact of pre‐admission antithrombotic therapy in hospitalised patients with COVID‐19: A multicenter observational study. Pharmacol Res 2020;159:104965. https://doi.org/10.1016/j.phrs.2020.104965
Chow JH, Khanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in‐hospital mortality in hospitalised patients with coronavirus disease 2019. Anesth Analg 2021;132(4):930‐941. https://doi.org/10.1213/ANE.0000000000005292
Harrison SL, Fazio‐Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID‐19 in the United States: A federated electronic medical record analysis. PLoS Med 2020;17(9):e1003321. https://doi.org/https://doi.org/10.1371/journal. pmed.1003321
Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials. Lancet 2018;392(10145):387‐399. https://doi.org/10.1016/S0140‐6736(18)31133‐4
Halbur CR, Gulbrandsen TR, West CR, Brown TS, Noiseux NO. Weight‐based aspirin dosing may further reduce the incidence of venous thromboembolism following primary total joint arthroplasty. J Arthroplasty 2021;36(12):3986‐3992. https://doi.org/10.1016/j.arth.2021.06.008
Salmon T, Titley M, Noori Z, Crosby M, Sankaranarayanan R. Anticoagulants and antiplatelets in COVID‐19: Impact on survival and thromboembolism development. Heart 2021;107(Suppl 1):A117. https://doi.org/10.1136/heartjnl‐2021‐BCS.150
MennuniMG,RendaG,GrisafiL,etal.Clinicaloutcomewithdifferentdosesoflow‐molecular‐weight heparin in patients hospitalised for COVID‐19. J Thromb Thrombolysis 2021;52(3):782‐790. https:// doi.org/10.1007/s11239‐021‐02401‐x
Tritschler T, Mathieu ME, Skeith L, et al. Anticoagulant interventions in hospitalised patients with COVID‐19: A scoping review of randomised controlled trials and call for international collaboration. J Thromb Haemost 2020;18(11):2958‐2967. https://doi.org/10.1111/jth.15094
Jiménez D, García‐Sanchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalised patients with coronavirus disease 2019: A systematic review and meta‐analysis. Chest 2021;159(3):1182‐1196. https://doi.org/10.1016/j.chest.2020.11.005
Musoke N, Lo KB, Albano J, et al. Anticoagulation and bleeding risk in patients with COVID‐19. Thromb Res 2020;196:227‐230. https://doi.org/10.1016/j.thromres.2020.08.035
Downloads
Published
Issue
Section
License
Copyright (c) 2022 V Pillay-Fuentes Lorente, R van Rensburg, M S Moolla, M McCaul, A Parker, J Taljaard, H Reuter, E H Decloedt
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
